Federal: HR7867

Bill Summary

HR 7867, the Infant Formula Safety Modernization Act of 2026, amends the Federal Food, Drug, and Cosmetic Act to require standardized pathogen and microorganism testing of infant formula products and manufacturing facilities. The bill mandates that manufacturers test finished products as well as designated manufacturing zones, maintain records of positive test results, and immediately notify the Secretary of Health and Human Services of any positive findings. The Commissioner of Food and Drugs must establish a list of critical pathogens and testing frequencies, and enforce consistent inspection standards across all infant formula manufacturers regardless of origin. Additionally, the Secretary must notify Congress within one business day of receiving notification of positive pathogen tests in finished formula or when the FDA issues an "official action indicated" inspection classification at a manufacturing facility.

Why It Matters to MAHA

This bill directly supports MAHA's core principle of transparency in healthcare and food safety by requiring prompt disclosure of safety test results and inspection findings to both manufacturers and Congress. The standardized testing and inspection protocols enhance patient autonomy by giving parents and healthcare providers access to critical safety information about the products they depend on for their infants' health. The emphasis on preventive testing across manufacturing environments reduces the risk of contaminated products reaching consumers, protecting vulnerable populations without restricting access to formula itself. The bill strengthens consumer protection through evidence-based safety standards while maintaining the availability of diverse formula options in the marketplace.